Stock AnalizPrestige Consumer Healthcare Inc. PBH
Biotechnology: Pharmaceutical Preparations · IPO 2005 · data as of November 13, 2026
Prestige Consumer Healthcare Inc. (PBH) is a healthcare company listed in the US with a market value of about $2.2B. In the twelve months to September 30, 2026 it had revenue of $1.2B and net income of $155M, a net margin of 13.3%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is value (4/5); the weakest is future growth (0/5).
Key numbers: a P/E of 14.3, a price to free cash flow of 10.2, 5-year revenue growth of 3% a year, a 5-year average ROIC of 7%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 67% above the current price.
Score: 2.0 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Positive free cash flow
- Interest covered more than 5 times
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
Checks not passed
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2B | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B | $943M | $963M | $976M | $1.0B | $882M |
| Net income | $155M | $190M | $215M | $209M | -$82M | $205M | $165M | $142M | -$36M | $340M | $69M |
| Free cash flow | $214M | $246M | $243M | $239M | $222M | $250M | $213M | $203M | $179M | $198M | $146M |
| EPS (diluted) | $3.24 | $3.91 | $4.29 | $4.17 | $-1.65 | $4.04 | $3.25 | $2.78 | $-0.69 | $6.34 | $1.30 |
| Net margin | 13.3% | 17.5% | 18.9% | 18.6% | -7.3% | 18.9% | 17.5% | 14.8% | -3.7% | 32.6% | 7.9% |
| ROIC | — | 7.9% | 8.9% | 9.3% | -0.7% | 8.4% | 8.4% | 7.4% | 2.2% | 5.3% | 4.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $66.20, 43% above the current price; targets range from $51.00 to $75.00; the consensus rating is “Buy”; expected EPS is $4.50 for the fiscal year ending March 31, 2027.
Frequently asked questions
What is Prestige Consumer Healthcare’s P/E ratio?
About 14.3, based on the last twelve months of diluted earnings per share (forward P/E about 9.4).
Is Prestige Consumer Healthcare stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 67% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Prestige Consumer Healthcare pay a dividend?
Not currently.
Is Prestige Consumer Healthcare a good stock to buy?
We do not give buy or sell advice. Prestige Consumer Healthcare scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.